Evidence map›Paper›PMID 22570742›Full record

ArticlePloS one2012

Role of stem cells in human uterine leiomyoma growth.

Masanori Ono, Wenan Qiang, Vanida Ann Serna, Ping Yin, John S Coon, Antonia Navarro, Diana Monsivais, Toshiyuki Kakinuma, Matthew Dyson, Stacy Druschitz and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 142 citations in OpenAlex.

  1. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. UTERINE FIBROIDS.Physiological reviews · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Masanori OnoDivision of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA.
Wenan Qiang
Vanida Ann Serna
Ping Yin
John S Coon
Antonia Navarro
Diana Monsivais
Toshiyuki Kakinuma
Matthew Dyson
Stacy Druschitz
Kenji Unno
Takeshi Kurita
Serdar E Bulun
Northwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Uterine Leiomyoma Research Center ProgramP01HD057877 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BULUN, SERDAR E. · 2009 to 2019
$12.2M
Mentoring For Success: Developing Fundamental Skills For Biomedical ResearchR25GM079300 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCGEE, RICHARD · 2007 to 2020
$6.6M
Xenograft Study on Growth-Control of Human Uterine LeiomyomataR01HD064402 · NICHD · OHIO STATE UNIVERSITY · PI KURITA, TAKESHI · 2010 to 2014
$1.6M
Molecular Etiology of Cervicovaginal Adenosis by in Utero Hormone ExposureR01CA154358 · NCI · OHIO STATE UNIVERSITY · PI KURITA, TAKESHI · 2010 to 2014
$1.5M
NCI NIH HHS 1R01CA154358NCI NIH HHS CA060553NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA154358NICHD NIH HHS 1R01HD064402NICHD NIH HHS 5P01HD057877NICHD NIH HHS P01 HD057877NICHD NIH HHS R01 HD064402NIGMS NIH HHS R25 GM079300
6 · The paper itself

Abstract

backgroundUterine leiomyoma is the most common benign tumor in reproductive-age women. Each leiomyoma is thought to be a benign monoclonal tumor arising from a single transformed myometrial smooth muscle cell; however, it is not known what leiomyoma cell type is responsible for tumor growth. Thus, we tested the hypothesis that a distinct stem/reservoir cell-enriched population, designated as the leiomyoma-derived side population (LMSP), is responsible for cell proliferation and tumor growth. PRINCIPAL

findingsLMSP comprised approximately 1% of all leiomyoma and 2% of all myometrium-derived cells. All LMSP and leiomyoma-derived main population (LMMP) but none of the side or main population cells isolated from adjacent myometrium carried a mediator complex subunit 12 mutation, a genetic marker of neoplastic transformation. Messenger RNA levels for estrogen receptor-α, progesterone receptor and smooth muscle cell markers were barely detectable and significantly lower in the LMSP compared with the LMMP. LMSP alone did not attach or survive in monolayer culture in the presence or absence of estradiol and progestin, whereas LMMP readily grew under these conditions. LMSP did attach and survive when directly mixed with unsorted myometrial cells in monolayer culture. After resorting and reculturing, LMSP gained full potential of proliferation. Intriguingly, xenografts comprised of LMSP and unsorted myometrial smooth muscle cells grew into relatively large tumors (3.67 ± 1.07 mm(3)), whereas xenografts comprised of LMMP and unsorted myometrial smooth muscle cells produced smaller tumors (0.54 ± 0.20 mm(3), p<0.05, n = 10 paired patient samples). LMSP xenografts displayed significantly higher proliferative activity compared with LMMP xenografts (p<0.05).

conclusionsOur data suggest that LMSP, which have stem/reservoir cell characteristics, are necessary for in vivo growth of leiomyoma xenograft tumors. Lower estrogen and progesterone receptor levels in LMSP suggests an indirect paracrine effect of steroid hormones on stem cells via the mature neighboring cells.

Indexed as

AdultAnimalsAntigens, SurfaceBase SequenceBlood CellsBone Marrow CellsCell CycleCell DifferentiationCell LineageCell ProliferationCell Transformation, NeoplasticCoculture TechniquesFemaleHumansLeiomyomaMediator ComplexAntigens, SurfaceMED12 protein, humanMediator Complex

Identifiers

PMID22570742
PMCPMC3343011
OpenAlexW2046521626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.